A priority list is one of the “urgent” measures the French pharma industry has called for as part of its contribution to the government’s 2023-25 roadmap for dealing with drug shortages, which is due to be published next month.
The French health minister, François Braun, has announced that he has received an initial list of 281 “critical” medicines whose supply needs to be ensured as the drug shortage problem continues to grow.
The list, which was drawn up by the health authorities, will sit alongside a list of medicines of “major therapeutic...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
